The serum levels of cytokines in thyroid heart failure patients
DOI:
https://doi.org/10.24959/cphj.19.1503Keywords:
interleukin, heart failure, thyroid toxicity, thyrotoxicosis, cytokinesAbstract
In recent years, the system of cytokines has a significant role in forming and progressing chronic heart failure of various etiologies (ischemic, inflammatory, infectious and allergic, etc.).
Aim. To study the activity of proinflammatory cytokines (interleukin-1α (Il-1α), interleukin-1β (Il-1β), interleukin-6 (Il-6) and interleukin-8 (Il-8) and anti-inflammatory cytokine (interleukin-4 (Il-4) in heart failure (HF) in thyrotoxicosis patients.
Materials and methods. 64 patients and 20 healthy volunteers were examined; they were distributed in 3 groups: group I (44 patients) patients with thyroid cardiomyopathy, group II (20) patients with no sign of cardiomyopathy and group III – 20 healthy volunteers. The serum levels of interleukines 1α, 1β, 4, 6 and 8 at admission, in 21 days and 6 months were measured.
Results. The level of IL-6 and IL-8 were significantly higher in patients with thyrotoxic HF compared to those without HF and healthy subjects. Correlation in Il-6 and Il-8 serum levels and severity and duration of HF were revealed. No correlation in Il-4 serum levels and HF was found.
Conclusions. It can be assumed that Il-6 and Il-8 are involved in the progression of heart failure and, less likely, in the formation of cardiomyopathy; however, for a more accurate identification of these regularities further studies are required.
References
Gianluigi, S., Lars, H. Lund. (2017). Global Public Health Burden of Heart Failure. Card Fail Rev, 3, 7–11. https://doi.org/10.15420/cfr.2016:25:2
Brickner, M. E., Hillis, L. D., & Lange, R. A. (2000). Congenital Heart Disease in Adults. New England Journal of Medicine, 342(4), 256–263. https://doi.org/10.1056/nejm200001273420407
Voronkov, L. H. (1999). Ukrainskyi kardiolohichnyi zhurnal, 1, 5–8.
Maggioni, A. P. (2001). HEART FAILURE: Treatment strategies for heart failure: beta blockers and antiarrhythmics. Heart, 85(1), 97–103. https://doi.org/10.1136/heart.85.1.97
Schmidt-Ott, U. M., & Ascheim, D. D. (2006). Thyroid hormone and heart failure. Current Heart Failure Reports, 3(3), 114–119. https://doi.org/10.1007/s11897-006-0010-1
Panchenkova, L. A., Troshina, E. A., Yurkova, T. E. (2000). Rossiyskie med. Vesti, 1, 18–25.
Efimov, A. S., Bodnar, P. N., Zelinskiy, B. A. (1983). Endokrinologiya. Kyiv, Vischa shkola, 47–52.
Gianoukakis, A. G., Khadavi, N., Smith, T. J. (2008). Cytokines, Graves’ Disease, and Thyroid-Associated Ophthalmopathy. Thyroid, 18, 953–958. https://doi.org/10.1089/thy.2007.0405
Liu, M., Chen, J., Huang, D., Ke, J., & Wu, W. (2014). A meta-analysis of proinflammatory cytokines in chronic heart failure. Heart Asia, 6(1), 130–136. https://doi.org/10.1136/heartasia-2013-010484
Downloads
Published
Issue
Section
License
Copyright (c) 2019 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
